Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemigatinib - Incyte Corporation

Next Previous
Drug Profile

Pemigatinib - Incyte Corporation

Alternative Names: IBI-375; INCB 54828; INCB-054828; Pemazyre

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Academic and Community Cancer Research United; Incyte Biosciences International; Incyte Corporation; Innovent Biologics; Knight Therapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Ethers; Fluorobenzenes; Morpholines; Pyridines; Pyrimidinones; Pyrroles; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Myeloproliferative disorders; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholangiocarcinoma
  • Registered Lymphoma; Myeloproliferative disorders
  • Phase II Adenosquamous carcinoma; Bladder cancer; Colorectal cancer; Endometrial cancer; Glioblastoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase I/II Cancer

Most Recent Events

  • 09 Dec 2023 Updated pharmacodynamic, safety and efficacy data from the phase II FIGHT-203 trial in Myeloproliferative disorders presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 04 Dec 2023 Launched for Cholangiocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)
  • 21 Nov 2023 Incyte Corporation completes a phase II FIGHT-210 trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, Germany, Italy, Spain (PO) (NCT05253807)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top